Literature DB >> 12768350

Regeneration of lipophilic antioxidants by NAD(P)H:quinone oxidoreductase 1.

Rosario I Bello1, Valerian E Kagan, Vladimir Tyurin, Francisco Navarro, Francisco J Alcaín, José M Villalba.   

Abstract

The aim of this work was to study the activity of NAD(P)H:(quinone acceptor) oxidoreductase 1 (EC 1.6.99.2) in the regeneration of lipophilic antioxidants, alpha-tocopherol, and reduced-coenzyme Q analogs. First, we tested whether or not two isoforms of the NAD(P)H:(quinone acceptor) oxidoreductase 1 designated as "hydrophilic" and "hydrophobic" (H. J. Prochaska and P. Talalay, Journal of Biological Chemistry 261: 1372-1378, 1986) show differential enzyme activities towards hydrophilic or hydrophobic ubiquinone homologs. By chromatography on phenyl Sepharose, we purified the two isoforms from pig liver cytosol and measured their reduction of several ubiquinone homologs of different side chain length. We also studied by electron paramagnetic resonance the effect of NAD(P)H:(quinone acceptor) oxidoreductase 1 on steady-state levels of chromanoxyl radicals generated by linoleic acid and lipooxygenase and confirmed the enzyme's ability to protect alpha-tocopherol against oxidation induced with H(2)O(2)-Fe(2+). Our results demonstrated that the different hydrophobicities of the isoforms do not reflect different reactivities towards ubiquinones of different side chain length. In addition, electron paramagnetic resonance studies showed that in systems containing the reductase plus NADH, levels of chromanoxyl radicals were dramatically reduced. Morever, in the presence of oxidants, alpha-tocopherol was preserved by NAD(P)H:(quinone acceptor) oxidoreductase 1, supporting our hypothesis that regeneration of alpha-tocopherol may be one of the physiologic functions of this enzyme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12768350     DOI: 10.1007/s00709-002-0068-x

Source DB:  PubMed          Journal:  Protoplasma        ISSN: 0033-183X            Impact factor:   3.356


  7 in total

Review 1.  Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry.

Authors:  G Morris; A J Walker; K Walder; M Berk; W Marx; A F Carvalho; M Maes; B K Puri
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

2.  Characterization of the threshold for NAD(P)H:quinone oxidoreductase activity in intact sulforaphane-treated pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Gary S Krenz; Adam J Gastonguay; Carol L Williams; Brian J Lindemer; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2011-01-14       Impact factor: 7.376

Review 3.  The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer.

Authors:  Michael Y Bonner; Jack L Arbiser
Journal:  Future Med Chem       Date:  2014       Impact factor: 3.808

4.  Preferential utilization of NADPH as the endogenous electron donor for NAD(P)H:quinone oxidoreductase 1 (NQO1) in intact pulmonary arterial endothelial cells.

Authors:  Robert D Bongard; Brian J Lindemer; Gary S Krenz; Marilyn P Merker
Journal:  Free Radic Biol Med       Date:  2008-09-20       Impact factor: 7.376

5.  Resveratrol Regulates the Expression of Genes Involved in CoQ Synthesis in Liver in Mice Fed with High Fat Diet.

Authors:  Catherine Meza-Torres; Juan Diego Hernández-Camacho; Ana Belén Cortés-Rodríguez; Luis Fang; Tung Bui Thanh; Elisabet Rodríguez-Bies; Plácido Navas; Guillermo López-Lluch
Journal:  Antioxidants (Basel)       Date:  2020-05-15

Review 6.  Endothelial dysfunction in neuroprogressive disorders-causes and suggested treatments.

Authors:  Gerwyn Morris; Basant K Puri; Lisa Olive; Andre Carvalho; Michael Berk; Ken Walder; Lise Tuset Gustad; Michael Maes
Journal:  BMC Med       Date:  2020-10-19       Impact factor: 8.775

Review 7.  A Molecular Neurobiological Approach to Understanding the Aetiology of Chronic Fatigue Syndrome (Myalgic Encephalomyelitis or Systemic Exertion Intolerance Disease) with Treatment Implications.

Authors:  Jean A Monro; Basant K Puri
Journal:  Mol Neurobiol       Date:  2018-02-06       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.